PredictImmune has announced that the National Institute for Health and Care Excellence (NICE) has published a Medtech Innovation Briefing (MIB) on the use of its PredictSURE IBD technology, for the prognosis of inflammatory bowel disease.
The advice is designed to support NHS and social care commissioners and staff who are considering using new medical devices and other medical or diagnostic technologies, commissioned by NHS England and produced in support of the NHS Five-Year Forward View, as one of a number of steps to help accelerate innovation in new treatments and diagnostics.
Paul Kinnon, chief executive of PredictImmune, commented: “We are very pleased to have received such a positive MIB. Given that these briefings are referenced not only across the UK, but also further afield, it is an important milestone and further validation for us as we continue to develop personalised approaches to treatment for patients with severe, debilitating diseases.
PredictSURE IBD is designed to predict long-term clinical outcomes when Crohn’s disease or ulcerative colitis are diagnosed, using a gene expression “signature” identified using quantitative polymerase chain reaction (PCR) technology.
Kinnon continued, “We strongly believe that helping to inform clinical decision making in the very early stages of diagnosis could vastly improve patient outcomes and quality of life. The evidence suggests that PredictSURE IBD enables us to do that for those suffering from Crohn’s disease and ulcerative colitis, which could have a major impact on treatment pathways in the future.”
The CE-marked prognostic test for guiding treatment options is thought to have the potential to improve information to allow clinicians to prescribe more appropriate therapy.
A spokesperson for Crohn’s and Colitis UK also stated that the test could potentially change the way patients with Crohn’s disease are treated by identifying the most effective treatment as early as possible.
